BioPoly knee implant for cartilage damage in the knee
Tests the BioPoly knee implant against usual surgery in adults with knee cartilage damage.
Key facts
- Who runs it
- BioPoly LLC
- Where
- Chesterfield, Fort Wayne, Indianapolis, Louisville, Redwood City, and Rochester, United StatesSee the 6 sites
- Trial code
- Registry title
- BioPoly® Partial Resurfacing Knee Implant IDE
- Status
- Recruiting
- People taking part
- 152 people, planned
- Started
- 17 Mar 2025
- Expected to end
- Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- BioPoly
- surgical standard of care (SSOC)
- Record updated
- 12 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with knee pain from a cartilage damage spot on the end of the thigh bone (distal femur) who can have knee surgery. They get either the BioPoly implant or standard surgery (microfracture or debridement).
- Age
- 30 to 65 years
- Sex
- All sexes
- Disease stage
- Cartilage lesion on the femoral condyle or trochlear facet, ICRS grade 2, 3 or 4. Lesion no larger than 3.1 cm2, less than 4mm deep, surrounded by normal or nearly normal cartilage. KOOS quality of life score ≤ 60.
- Earlier treatment
- Non-surgical treatment (such as NSAID, injections, physical therapy) must have failed after at least 2 months, or earlier knee surgery (such as debridement, marrow stimulation, high tibial osteotomy) must have failed at least 12 months ago. People whose ACI, OATS or Allograft treatment failed cannot join.
Main reasons for not taking part
- Body mass index (BMI) ≥ 35
- Advanced osteoarthritis in the knee (Kellgren-Lawrence Grade 4), autoimmune arthritis or gout
- Osteoporosis, osteopenia or other bone disease, or weak bone under the lesion
- Knee misalignment over 5 degrees, unrepaired ligament instability, or total meniscus removal
- Pregnant or planning pregnancy, uncontrolled diabetes, or allergy to titanium alloy, UHMWPE or hyaluronic acid
The registry criteria, word for word
Show all 32 criteriaShow less
Who can take part
- Patient is between 30 and 65 years of age25
- KOOS quality of life score ≤ 60
- In the opinion of the Investigator, the patient has the understanding and willingness to comply with all study requirements including the Post-Operative rehabilitation and follow-up protocol
- Patient has cartilage lesion that has failed non-surgical conservative therapy (e,g, anti-inflammatory (NSAID), viscosupplementation, steroid injection, physical therapy, or activity modification) after at least 2 months of beginning the therapy or failed surgical conservative therapy (e.g. debridement/lavage, marrow stimulation, or alignment high tibial osteotomy) that was performed at least 12 months ago in the index knee and is a candidate for surgical intervention
- Patient has cartilage lesion located in the femoral condyle or trochlear facet
- Patient has lesion(s) classified as ICRS grade 2, 3 or 4
- Patient's lesion size may not exceed 3.1 cm2 and must be circumscribed by a 1.5 cm or 2.0 cm diameter circle, or 1.5 cm (M-L) by 2.4 cm (A-P) oval of normal or nearly normal (ICRS grade 0 or 1) cartilage, with an overall depth less than 4mm from the articulating surface
- Patient has subchondral bone quality that is non-osteoporotic and is sufficient to support the implant. The quality of bone will be assessed by the surgeon intraoperatively with a surgical instrument such as an awl
Who cannot take part
- Contralateral knee is known to have symptomatic cartilage, meniscal, or ligamentous lesions, generalized osteoarthritis, or requires surgery
- Patient has a cartilage lesion that is being treated with a non-surgical conservative therapy (e,g, anti-inflammatory (NSAID), viscosupplementation, steroid injection, physical therapy, or activity modification) and it has been < 2 months since beginning treatment or the patient's cartilage lesion has failed surgical therapy (e.g. debridement/lavage, marrow stimulation, alignment (high tibial osteotomy)) in the index knee and it has been < 12 months since the surgical treatment
- Patient is participating in other studies and/or receiving any other simultaneous therapy in index knee
- Patient has an uncorrected tear of the meniscus of the index knee. (Partial meniscectomy that retains >50% of the meniscus is allowed prior to or concurrently with the cartilage treatment procedure. Meniscus suture repair is allowed prior to or concurrently with the cartilage treatment procedure if >50% of the functional meniscus remains.)
- More than one implant is required to accommodate defect in the index knee
- Patient has inadequate bone stock (e.g., cysts, osteoporosis) underlying the lesion site as determined intra-operatively by the investigator; As determined by the investigator through use of an awl or a similar instrument to determine if the bone quality is insufficient to support the BioPoly device; If the cause of inadequate bone stock is due to cysts or to the boney portion of an osteochondral lesion being excessive, then the investigator may opt to fix the implant with cement rather than exclude the patient for inadequate bone stock
- Patient has autoimmune arthritis, as diagnosed by Investigator
- Patient has uncorrected ligamentous instability (good joint stability in the index joint with a Grade 1 Lachman or less, no pivot shift for ACL insufficiency and no posterior translation of more than grade 1; no deficits in flexion or extension of > 10 degrees compared to contralateral knee) in the index knee
- Patient currently reports or has a documented history of uncontrolled diabetes
- Patient currently has any condition, therapy, or medication known to impair bone healing
- Patient has had an active systemic infection or joint infection in index knee over the last 12 months
- Patient has an allergy to titanium alloy (Ti-6Al-4V), ultrahigh molecular weight polyethylene (UHMWPE), or hyaluronan/ hyaluronic acid (HA)
- Patients with osteoporosis, osteopenia, Paget's disease, osteomalacia or any other metabolic bone disease; a. Osteoporosis is defined as Simple Calculated Osteoporosis Risk Estimation (SCORE) above 6 and DXA T-score < -2.5 or QCT T-score < 80mg/cubic cm. History of a fragility fracture requires that a DXA scan or QCT scan is completed
- Patient has body mass index (BMI) ≥ 35
- Patient has advanced degenerative osteoarthritis in index knee (Kellgren-Lawrence Grade 4 and/or diagnosed intraoperatively)
- Patient has gout, by Investigator diagnosis or patient-reported history within last 12 months
- Patient has a cartilage lesion that is being treated that has failed ACI, OATS or Allograft treatment
- Patient has malalignment of the index knee (>5 degrees weight bearing varus or valgus)
- Patient has bipolar articular cartilage involvement (or kissing lesions) of the ipsilateral compartment (i.e. greater than ICRS Grade 2 on the opposing articular surface) in the index knee
- Patient has undergone a total meniscectomy of index knee
- Patient has undergone patellofemoral arthroplasty of the index knee
- Patient is pregnant or is planning to become pregnant (for female patients only) at any point during the duration of the study
- Patient has legal involvement or any other issue that would hinder completion of the two-year follow-up period
- Patient has an additional cartilage lesion(s) (ICRS Grade 3 or 4) in the index knee, located on the patella, trochlea, tibia, or non-weight bearing area of index condyle that requires treatment
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 65 years old?
Where in United States
- Washington University OrthopedicsChesterfield, United StatesContact: Susan BrandonTaking people
- Dupont HospitalFort Wayne, United StatesContact: Ian Nelson, MD (principal investigator)Taking people
- OrthoIndyIndianapolis, United StatesContact: Sheila Schwartz, R.Ph.No longer taking part
- University of LouisvilleLouisville, United StatesContact: Jolynn Roberts Research CoordinatorTaking people
- Stanford Medicine Dept of Orthopaedic SurgeryRedwood City, United StatesContact: Allen SeoTaking people
- Mayo ClinicRochester, United StatesContact: Noelle DrapeauTaking people
About the trial
What the trial wants to find out
The goal of this randomized controlled clinical trial is to demonstrate the safety and effectiveness of the BioPoly® Partial Resurfacing Knee Implant for the treatment of cartilage defects of the distal femur in adult patients with knee pain and symptoms who are candidates for surgical intervention of the knee compared to outcomes for the control group.
Read full original descriptionShow less
The primary effectiveness endpoint is Month 24 composite clinical success (CCS) defined by:
* no secondary surgical intervention (SSI) and * an improvement from baseline in the Knee injury and Osteoarthritis Outcome Score (KOOS) total score (scaled 0 to 100) of at least 10 points.
Researchers will compare the CCS for the investigational device group to a control group receiving the standard of care, either microfracture or debridement).
Subjects randomized to the investigational group will receive the BioPoly Knee device and those randomized to the control group will receive the current standard of care, either microfracture or debridement.
The 2 groups in the trial
- InvestigationalExisting treatment, for comparison
BioPoly Knee device
Treatment: BioPoly
- ControlExisting treatment, for comparison
Surgical Standard of Care Group: either Microfracture or debridement procedure
Treatment: surgical standard of care (SSOC)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Pivotal, Prospective, Randomized, Controlled, Multicenter Clinical Trial of BioPoly® Partial Resurfacing Knee Implant for Treatment of Focal Cartilage Lesions of the Distal Femur
- Plain-language title
- BioPoly knee implant for cartilage damage in the kneeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT06915363, who can take part
- Record updated
- 12 November 2026